Recombinant anti- human ErbB2/HER2 Antibody (Trastuzumab)
Figure-1: Antiproliferative activity of Samceptin was assayed in comparison with Herceptin using ADCC Reporter Bioassay Kit from Promega (Cat #G7010) in SK-BR-3 cells. Result indicated that Samceptin potency is at par with Herceptin.
Roll over image to zoom in
Shipping Info:
Order now and get it on Tuesday March 28, 2023
Same day delivery FREE on San Diego area orders placed by 1.00 PM
| Format : | Purified |
| Amount : | 100 μg |
| Purification : | Purity: >98.0% as determined by SEC-HPLC & SDS-PAGE. |
| Content : | In Trehalose, Histidine, Histidine-Cl, Tween-20 |
| Storage condition : | Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles. |
| AA sequence : | PepMap Analysis of N terminal amino acids sequence: H chain: EVQLVESGGGLVQPG, L chain: DIQMTQSPSSLSASV |
Target: ErbB2
Trade name: Samceptin
Generic name: Trastuzumab
Product Origin: Recombinant in CHO cells
Product Construction: Immunoglobulin G1, anti-(human p185neu receptor) (human-mouse monoclonal rhuMab HER2 g1- chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain, dimer.
The drug Trastuzumab (Brand name Herceptin®, From Roche/Genentech) is a monoclonal antibody and works by targeting breast cancer cells that overexpress the HER2 protein. Overexpression (or amplification) of the HER2 protein is associated with accelerated cell division. By binding to the protein receptors on these cells, Trastuzumab interrupts the growth signal, thereby slowing the growth and spread of tumors. Approximately 20% of breast cancers overexpress the HER2 protein. Amplification of HER2 in breast cancer cells has been correlated with adverse prognostic factors such as large tumor size, high nuclear grade, and decreased expression of estrogen and progesterone hormone receptors. HER2 amplification has also been associated with reduced disease-free survival, and overall survival, for women with node-positive or node negative disease. Trastuzumab (anti-p185, rhuMab HER2), which is a humanized monoclonal antibody that binds to the HER2 protein. HER-2 is a transmembrane spanning receptor-like protein, which is structurally related to the epidermal growth factor receptor and has been shown to inhibit the proliferation of human tumor cells that overexpress HER2 both in vitro and in vivo. The developed biosimilar to Herceptin, designated as Samceptin. The biochemical characterizations and the functional assays suggest that Samceptin is highly similar in structure and activity to Herceptin.
*Disclaimer: Herceptin® is a registered trademark of Genentech, Inc. Samceptin can only be used for research purposes. Not to be used as diagnostic for therapeutic purposes.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
| Subcellular location: | Cytoplasm, Nucleus |
| Post transnational modification: | Autophosphorylated. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit (Probable). Ligand-binding increases phosphorylation on tyrosine residues (PubMed:27134172). Signaling via SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). Dephosphorylated by PTPN12 (PubMed:27134172). |
| Tissue Specificity: | Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth. |
| BioGrid: | 108376. 234 interactions. |
|
There are currently no product reviews
|
